Prior adalimumab exposure alters infliximab pharmacokinetics and trough targets in pediatric Crohn's disease.

What To Know

This retrospective pediatric study compared infliximab (IFX) trough levels and endoscopic remission (ER) between children who started IFX as first-line biologic and those who received IFX after prior adalimumab (ADL).

The researchers found that prior ADL exposure was associated with lower observed IFX trough levels, yet rates of endoscopic remission were comparable; ADL-exposed patients achieved ER at lower IFX troughs than biologic‑naive patients.

What to take from this study: it suggests that prior exposure to another anti-TNF (adalimumab) may change the exposure-response relationship for infliximab in pediatric Crohn's disease. That could have implications for how clinicians interpret IFX drug levels and consider dosing or monitoring in children who switch biologics.

The study is retrospective and based on medical-record review; it reports associations rather than proving causation. It does not itself establish new trough targets or dosing recommendations, but it highlights a potential need for tailored therapeutic-drug-monitoring strategies in patients with prior biologic exposure.

If you are a parent or clinician of a child switching biologics, this study supports discussing individualized monitoring (drug levels and clinical/endoscopic outcomes) with your care team rather than relying on one-size-fits-all targets.